STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceuticals Holding Corp. - TNXP STOCK NEWS

Welcome to our dedicated page for Tonix Pharmaceuticals Holding news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding stock.

Tonix Pharmaceuticals Holding Corp. (symbol: TNXP) is a pioneering biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics to treat and prevent human diseases. With a focus on central nervous system (CNS) disorders, Tonix is at the forefront of addressing major public health challenges.

One of Tonix's key projects is Tonmya, aimed at treating PTSD, which is currently in advanced stages of development. Additionally, the company is working on TNX-601 (tianeptine oxalate), a daytime treatment for PTSD, and TNX-801, a synthetic version of the horsepox virus, intended as a potential smallpox vaccine, both at the pre-IND (Investigational New Drug) application stage.

The company’s immunology development portfolio includes TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), being developed to prevent allograft rejection and treat autoimmune diseases. This portfolio demonstrates Tonix's commitment to addressing both organ transplant rejection and autoimmunity, as well as cancer.

Tonix’s mission to alleviate suffering extends beyond CNS disorders and immunology, as it is also exploring therapeutic solutions for rare and infectious diseases. Their dedication to research and innovation has established partnerships with reputable institutions, such as Massachusetts General Hospital, ensuring that their projects are backed by cutting-edge science and expertise.

For more information, visit Tonix Pharmaceuticals Holding Corp.

News

Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. has entered into a securities purchase agreement for the purchase and sale of 7,000,000 shares of its common stock and warrants in a public offering. The gross proceeds of the offering will be approximately $7 million. The company intends to use the net proceeds for working capital, facility build-out, and product acquisition or licensing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.89%
Tags
offering
-
News

Tonix Pharmaceuticals Announces Proposed Public Offering

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.89%
Tags
offering
News

Tonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023

Rhea-AI Summary
Tonix Pharmaceuticals announced that development of TNX-4300 (estianeptine) will be prioritized over TNX-601 ER for the treatment of major depressive disorder. Recent findings have shown that estianeptine improves memory and cognition in vivo and restores neuroplasticity in neurons. Tonix intends to accelerate enrollment for the Phase 2 UPLIFT1 trial and expects to report topline data in Q4 2023. They are also accelerating enrollment in the RESILIENT study for TNX-102 SL for fibromyalgia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
earnings clinical trial
-
News

Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test

Rhea-AI Summary
Tonix Pharmaceuticals announces data supporting the memory- and cognition-enhancing effects of TNX-601 ER and TNX-4300 in Alzheimer's disease and other psychiatric and neurodegenerative conditions. The findings show that tianeptine and estianeptine improve memory and cognition. TNX-601 ER is being tested in a Phase 2 trial for major depressive disorder, with results expected in Q1 2024. TNX-4300 is in preclinical development for mood disorders and neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
none
-
News

Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
clinical trial
News

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
clinical trial
-
News

Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National Academies

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
covid-19
-
News

Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
acquisition
News

Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.63%
Tags
acquisition

FAQ

What is the current stock price of Tonix Pharmaceuticals Holding (TNXP)?

The current stock price of Tonix Pharmaceuticals Holding (TNXP) is $0.19 as of November 22, 2024.

What is the market cap of Tonix Pharmaceuticals Holding (TNXP)?

The market cap of Tonix Pharmaceuticals Holding (TNXP) is approximately 38.2M.

What is the main focus of Tonix Pharmaceuticals Holding Corp.?

Tonix focuses on developing, licensing, and commercializing therapeutics to treat and prevent human diseases, with a primary focus on central nervous system disorders.

What is Tonmya?

Tonmya is a treatment developed by Tonix Pharmaceuticals aimed at addressing PTSD. It is one of the company's key projects.

What are TNX-601 and TNX-801?

TNX-601 (tianeptine oxalate) is a candidate for daytime treatment of PTSD and TNX-801 is a synthetic version of the horsepox virus, intended as a potential smallpox-preventing vaccine.

What is TNX-1500?

TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand, being developed to prevent allograft rejection and treat autoimmune diseases.

Which institutions is Tonix Pharmaceuticals affiliated with?

Tonix has established partnerships with reputable institutions, including Massachusetts General Hospital, to support their research and development projects.

How can I get more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their official website, www.tonixpharma.com.

What areas of disease does Tonix Pharmaceuticals focus on?

Tonix focuses on central nervous system disorders, organ transplant rejection, autoimmunity, cancer, rare diseases, and infectious diseases.

What stage are TNX-601 and TNX-801 in?

Both TNX-601 and TNX-801 are at the pre-IND (Investigational New Drug) application stage.

Who can I contact for investor relations at Tonix Pharmaceuticals?

For investor relations, you can contact Jessica Morris at investor.relations@tonixpharma.com or Peter Vozzo at peter.vozzo@westwicke.com.

Who can I contact for media inquiries at Tonix Pharmaceuticals?

For media inquiries, you can contact Katie Dodge at kdodge@lavoiehealthscience.com.

Stock TNXP logo
Tonix Pharmaceuticals Holding Corp.

Nasdaq:TNXP

TNXP Rankings

#5006 Ranked by Market Cap
N/A Ranked by Dividends

TNXP Stock Data

38.16M
186.60M
0.17%
0.23%
5.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHATHAM